Mini-Stern Trial: A randomised trial comparing mini-sternotomy to full median sternotomy for aortic valve replacement by Nair, SK et al.
LSHTM Research Online
Nair, SK; Sudarshan, CD; Thorpe, BS; Singh, J; Pillay, T; Catarino, P; Valchanov, K; Codispoti, M;
Dunning, J; Abu-Omar, Y; +5 more... Moorjani, N; Matthews, C; Freeman, CJ; Fox-Rushby, JA;
Sharples, LD; (2018) Mini-Stern Trial: A randomised trial comparing mini-sternotomy to full median
sternotomy for aortic valve replacement. The Journal of thoracic and cardiovascular surgery. ISSN
0022-5223 DOI: https://doi.org/10.1016/j.jtcvs.2018.05.057
Downloaded from: http://researchonline.lshtm.ac.uk/4648558/
DOI: https://doi.org/10.1016/j.jtcvs.2018.05.057
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
https://researchonline.lshtm.ac.uk
 1 
 
Mini-Stern Trial: A randomised trial comparing mini-sternotomy to full median 1 
sternotomy for aortic valve replacement 2 
Authors:  3 
Sukumaran K Nair FRCS(CTh),1,4 Catherine D Sudarshan FRCS(CTh),1 Benjamin S Thorpe 4 
PhD,2 Jeshika Singh PhD,3 Thasee Pillay FRCS(CTh),4 Pedro Catarino FRCS(CTh),1 Kamen 5 
Valchanov MD,1 Massimiliano Codispoti FRCS(CTh),1 John Dunning FRCS(CTh),1 Yasir 6 
Abu-Omar FRCS(CTh), 1 Narain Moorjani FRCS(CTh),1 Claire Matthews BSc,1 Carol J 7 
Freeman MPhil,1 Julia A Fox-Rushby PhD,3  Linda D Sharples PhD.5 8 
Institutions: 9 
1.  Papworth Hospital, Cambridge, UK 10 
2.  Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK  11 
3.  Health Economics Research Group (HERG), Brunel University London, London, UK 12 
4.  Freeman Hospital, Newcastle upon Tyne, Newcastle upon Tyne, UK 13 
5.  London School of Hygiene and Tropical Medicine, Keppel Street, London, UK 14 
Conflict of interest statement and source of funding: 15 
This work was supported by the National Institute for Health Research (NIHR) under its 16 
Research for Patient Benefit (RfPB) Programme (grant number PB-PG-0408-16296).  The 17 
views expressed are those of the author(s) and not necessarily those of the NHS, NIHR or 18 
Department of Health. 19 
Corresponding author and contact information:  20 
Mr Sukumaran Nair, Consultant Cardiac Surgeon, Golden Jubilee National Hospital, 21 
Agamemnon Street, Glasgow , G81 4DY, United Kingdom 22 
Telephone: 0044 141 951 5280.  23 
Email: Sukumaran.Nair@gjnh.scot.nhs.uk  24 
Trial Registration: ISRCTN, number 58128724  25 
 2 
 
Article word count: 3500 (including main text and figure legends) 26 
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contribution form with detailed justification of authorship will be submitted along with the 32 
revised manuscript on acceptance for publication.   33 
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Glossary of Abbreviations 35 
 36 
AVR  aortic valve replacement  37 
mAVR  minimal access aortic valve replacement 38 
BMI  body mass index 39 
CI  95% confidence interval 40 
COPD  chronic obstructive pulmonary disease  41 
CPB  cardiopulmonary bypass 42 
FEV1   forced expiratory volume in one second 43 
FS  full median sternotomy 44 
HR  hazard ratio 45 
HRQoL health-related quality of life 46 
ICER  incremental cost-effectiveness ratio 47 
LVEF  left ventricular ejection fraction  48 
MS  mini-sternotomy 49 
NHS  National Health Service 50 
OR  odds ratio  51 
QALY  quality-adjusted life year 52 
RCT  randomised control trial  53 
SAE   serious adverse event 54 
SD  standard deviation 55 
TLCO   transfer factor of the lung for carbon monoxide 56 
TOE  transoesophageal echocardiogram 57 
UK  United Kingdom 58 
  59 
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Central Message 60 
 61 
In the UK NHS, compared to conventional median sternotomy approach for surgical AVR, 62 
mini-sternotomy did not hasten recovery or hospital discharge, and was not cost-effective.    63 
 5 
 
Perspective Statement 64 
Minimal access surgery is appealing for its perceived advantages including better patient 65 
recovery, satisfaction and cost-effectiveness.  This RCT conducted within the UK NHS 66 
setting did not demonstrate quicker patient recovery or cost-effectiveness associated with 67 
mini-sternotomy compared to full median sternotomy approach.  These findings are relevant 68 
to physicians, patients and health care funders.  69 
70 
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Structured Abstract 71 
Objective:  Aortic valve replacement (AVR) can be performed either through full median 72 
sternotomy (FS) or upper mini-sternotomy (MS).  The Mini-Stern trial aimed to establish 73 
whether MS leads to quicker postoperative recovery and shorter hospital stay after first-time 74 
isolated AVR.   75 
Methods:   This pragmatic, open-label, parallel RCT compared MS with FS for first-time 76 
isolated AVR in two UK NHS hospitals. Primary endpoints were duration of postoperative 77 
hospital stay and the time to fitness for discharge from hospital after AVR, analysed in the 78 
intent-to-treat population.  79 
Results:  In this RCT, 222 patients were recruited and randomised (118 MS, 104 FS).    80 
Compared to FS patients, MS patients had longer hospital stay (mean 9.5 vs. 8.6 days) and 81 
took longer to achieve fitness for discharge home (mean 8.5 vs. 7.5 days). Adjusting for valve 82 
type, sex and surgeon, hazard ratios (HR) from Cox models did not show a statistically 83 
significant effect of MS (relative to FS) on either hospital stay (HR 0.874, 95% CI 0.668-84 
1.143, p-value 0.3246) or time to fitness for discharge (HR 0.907, 95% CI 0.688-1.197, p-85 
value 0.4914).  During mean follow up of 760 days (MS:745 and FS:777 days), 12 (10%) MS 86 
and 7 (7%) FS patients died (HR 1.871, 95% CI 0.723-4.844, p-value 0.1966). Average extra 87 
cost for MS was £1,714, during the first 12 months after AVR.  88 
Conclusions:  Compared to FS for AVR, MS did not result in shorter hospital stay, faster 89 
recovery or improved survival and was not cost-effective.  MS approach is not superior to FS 90 
for performing AVR. 91 
Word count for Abstract:  248  92 
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Introduction 93 
Aortic valve replacement (AVR) is the second commonest cardiac surgery in the UK [1] with 94 
an increasing proportion of older patients [1, 2].  Minimal access AVR (mAVR) might 95 
shorten hospital stay and postoperative recovery period and could be beneficial if offered 96 
safely and cost-effectively.   97 
 98 
Currently, most AVRs are performed safely through full median sternotomy (FS) [2-6].  99 
However, mAVR may be associated with less postoperative pain, blood loss, pulmonary and 100 
wound complications and shorter hospital stay [2]. The most commonly practised mAVR 101 
involves mini-sternotomy (MS), which could potentially hasten postoperative recovery, 102 
shorten hospital stay and improve patient satisfaction [2-10]. 103 
 104 
Most studies comparing MS and FS for AVR are non-randomised.  Although systematic 105 
reviews with meta-analyses [11, 12] have been conducted, inadequate statistical power and 106 
heterogeneity of studies calls for prospective, randomised control trials (RCTs) to assess 107 
benefits and risks of mAVR.  Published evidence on cost-effectiveness comparing MS to FS 108 
is sparse and weak. A recent review comparing cost-effectiveness of FS and MS called for a 109 
well-designed RCT to evaluate cost-effectiveness of mAVR up to at least a year after surgery 110 
[13]. Recently, a propensity-matched study from the UK national data concluded that mAVR 111 
is safe and was associated with shorter postoperative hospital stay [14]. The authors 112 
concluded that although general clinical equipoise exists between FS and MS, it is essential 113 
to have a well-constructed and adequately powered RCT before widespread adoption of MS.  114 
This retrospective study did not analyse cost-effectiveness of either surgical approach. 115 
 116 
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The Mini-Stern trial assessed whether MS is superior to FS in shortening postoperative 117 
recovery time and improving patient outcomes without compromising patient safety. It also 118 
assessed cost-effectiveness of MS from the perspective of the UK NHS as a health care 119 
provider. 120 
 121 
Materials and Methods 122 
Mini-Stern was a two-centre, pragmatic, open-label RCT conducted in the UK.  Patients were 123 
randomised (1:1) to AVR either by MS or FS.  124 
 125 
 Sample Size 126 
Considering four published RCTs [5, 6, 9, 10] and two cohort studies [7, 8], a 20% reduction 127 
in hospital stay from 11.7 to 9.36 days was considered clinically significant.  Based on an 128 
internal audit of 252 first-time elective AVRs performed at Papworth Hospital in 2007/08 129 
(mean hospital stay 11.7 days, SD 6.2), to detect this change with 80% power and 2-sided 130 
significance of 5%, 110 patients per group were required. As randomisation was performed 131 
on the day of surgery after induction of anaesthesia and introduction of the transoesophageal 132 
echocardiogram (TOE) probe, no subjects dropped out between randomisation and surgery 133 
thereby making the total trial recruitment target, 220 patients. 134 
 135 
Recruitment 136 
Adult patients undergoing first-time isolated AVR were included.  Exclusion criteria included 137 
emergency AVR, LVEF≤ 30%, chest wall deformities, severe COPD (FEV1 or TLCO < 40% 138 
predicted), BMI > 35kg/m2, concomitant cardiac surgery, redo-surgery and inability to 139 
perform TOE. Details of patient enrolment are given in the online protocol. 140 
 141 
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Randomisation 142 
Randomisation (1:1) used random permuted blocks of variable lengths (6 or 8), stratified by 143 
surgeon and valve prosthesis (bio-prosthetic or mechanical). Random allocations were pre-144 
generated, held in secure files by Papworth Trials Unit.  During early days of the trial, TOE 145 
probe could not be passed in four patients due to technical reasons.  These patients underwent 146 
the allocated procedure and were included in the trial. Later the Trial Steering Committee 147 
decided that under such circumstances, MS would be unsafe and patients should be excluded 148 
from the trial to FS.  Since eligibility for MS required TOE, in order to avoid post-149 
randomisation drop-out, group allocation for the study subjects was retrieved via telephone 150 
by theatre staff soon after anaesthesia and introduction of the TOE probe.  Due to the nature 151 
of interventions, this trial could not be blinded.  152 
 153 
Outcomes 154 
Primary endpoints:  Two closely related primary endpoints were measured.  Firstly, length 155 
of postoperative hospital stay (days between surgery and actual hospital discharge) which is 156 
easily measured, a surrogate for early postoperative events and sensitive to outcomes that 157 
affect health-related quality of life (HRQoL).  Secondly, the interval in days between surgery 158 
and the patient being medically fit for discharge. To reduce investigator bias, standard 159 
discharge criteria were followed to decide the day of fitness for discharge. This endpoint was 160 
chosen to address exogenous effects (social factors, lack of transport, non-availability of 161 
space in nursing homes etc.) that commonly delay hospital discharge in the UK. 162 
 163 
Clinical secondary endpoints: duration of surgery,  total theatre time,  aortic cross-clamp 164 
and cardiopulmonary bypass (CPB) times, blood loss in the first 12 hours after surgery,  165 
transfusion of blood and clotting products in the first 48 hours (blood transfusion trigger was 166 
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haemoglobin level < 80g/L),  frequency of re-intubation,  time to initial extubation, 167 
mediastinal drain removal and first independent mobilisation,  daily pain scores at rest and on 168 
deep breath (over the first ten days or until hospital discharge) on a scale of 0 to 10, LVEF 169 
and severity of para-prosthetic regurgitation at hospital discharge and at 6 months, and time 170 
to all-cause death. Definitions of adverse events and details of their reporting are in the online 171 
protocol.  To exclude bias, clinical outcome data were collected by research team  who were 172 
not involved in routine care of subjects, following standardised protocols.   173 
 174 
Non-clinical secondary endpoints:  Health-related Quality of Life and Healthcare resource 175 
use. 176 
HRQoL:  Patients completed EQ-5D-3L [15] and SF-36 [16, 17] questionnaires at baseline, 177 
6 weeks, 6 months and 12 months following surgery. EQ-5D-3L was repeated on fourth 178 
postoperative day and at discharge.   179 
Healthcare resource use:   Patient-specific resource use collected from hospital records and 180 
patient interviews during the primary admission included phases of care including operative 181 
surgery, critical care, post-surgical ward care and medications. Post-discharge resource use 182 
included attending wound clinics, community nurse visits, physiotherapy sessions,  183 
occupational therapy services, medical tests, cost of  analgesics and other drugs and further 184 
hospitalisation within the first year after AVR. 185 
 186 
Surgical details 187 
All participating surgeons were consultants experienced in performing AVR by both FS and 188 
MS. They followed the operative surgical protocol as described below. 189 
MS approach: With the patient anaesthetised as per standard protocol, skin was incised from 190 
half-way between the suprasternal notch and the sternal angle to the level of the fourth 191 
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intercostal space, measuring approximately 8cm. The manubrium was divided in the midline 192 
from the suprasternal notch inferiorly and then into the right 4th intercostal space. Thymus 193 
was divided and pericardium opened exposing the ascending aorta, aortic root and right atrial 194 
appendage.  A loading dose of unfractionated heparin 300U/kg followed by boluses of 5000U 195 
was administered to achieve activated clotting time above 450 seconds.  Aorta was 196 
cannulated using a wired flexible aortic cannula. Right atrial appendage was cannulated using 197 
a flat venous cannula and CPB commenced.  The ascending aorta was cross-clamped and 198 
intermittent, antegrade, cold blood cardioplegia administered. The aorta was then incised 199 
open in an oblique or transverse fashion, the diseased valve excised and annulus decalcified.  200 
A suitably sized aortic valve prosthesis was inserted using either horizontal mattress, 2-0 201 
Ethibond sutures or semi-continuous, 2-0 Prolene sutures. Surgeons adopted either of these 202 
suture techniques and adhered to the same technique irrespective of the type of valve 203 
prosthesis or the surgical approach.  Aortotomy was then closed, heart de-aired, right atrial 204 
and ventricular epicardial pacing wires inserted and patient weaned off CPB.  After 205 
confirming satisfactory functioning of the aortic valve prosthesis by TOE, heparin was 206 
reversed with protamine (1mg/100U of heparin).  Chest drains were inserted into the anterior 207 
mediastinum, posterior pericardial space and pleural space if necessary.  Sternal wires were 208 
inserted and incision closed in layers. Conversion to FS was performed to ensure patient 209 
safety if access was difficult or if intraoperative complications occurred.    210 
 211 
FS approach:  Anaesthesia and positioning of patients was the same as for MS approach.  212 
The skin incision was made between the suprasternal notch and the xiphoid process and 213 
sternum divided in the midline from the suprasternal notch to the xiphoid process.  A two-214 
stage venous cannula was used for atrial cannulation.  Remaining steps were similar to MS 215 
approach. 216 
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 Statistical analysis 217 
Analyses of primary and secondary endpoints used intention-to-treat and included all 218 
randomised patients. Unless stated otherwise, statistical models included treatment (MS vs. 219 
FS), valve (mechanical vs. bio-prosthetic) and sex as fixed effects, and surgeons as random 220 
effects. Hypothesis testing was two-sided at the 5% significance level, with no adjustments 221 
for multiple testing. All confidence intervals (CI) were estimated at the 95% confidence level.  222 
Distributions of time-to-event endpoints were compared between study groups using Kaplan-223 
Meier curves and log-rank tests (stratified by sex, valve and surgeon). Hazard ratios (HR) for 224 
MS relative to FS were estimated from a Cox model. The null hypothesis of no treatment 225 
effect (HR = 1) was tested. Patients who were lost to follow-up, withdrew or died before the 226 
event were censored at the latest time they were known to be event-free. Models were 227 
checked by plotting Schoenfeld and deviance residuals.  For primary endpoints, Cox models 228 
were re-fitted using the per-protocol population and in sensitivity analyses (Appendix A. 229 
Table A4).   230 
Need for reintubation and other dichotomous endpoints were compared between groups by 231 
estimating a MS/FS odds ratio (OR) via logistic regression. EQ-5D, SF-36 and pain scores 232 
were modelled using repeated measures linear regression. Where possible, random intercepts 233 
and random time coefficients for patients were included. For EQ-5D and SF-36, fixed effects 234 
for baseline scores were included. Models were fitted using complete cases, then re-fitted 235 
with multiple imputation of missing scores via chained equations.  236 
Serious adverse events (SAEs) were analysed in the safety population according to 237 
intervention received. Patients randomised to MS who crossed over to FS prior to surgery 238 
were considered to have received FS; those who crossed over after MS had commenced were 239 
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considered to have received MS. Rates of SAEs were explored using Poisson regression with 240 
a random patient effect.     241 
 CONSORT guidelines [18] were followed. Analyses were performed in SAS version 9.4 242 
(SAS Institute Inc., Cary, NC, USA). No interim analyses were undertaken but reports were 243 
presented annually to the Data Monitoring and Ethics Committee.  244 
Economic analysis  245 
Unit costs were obtained from nationally published sources in the UK [19, 20, 21, 22] or 246 
from the Finance department, Papworth Hospital when the former did not provide the 247 
required information.  Total cost per patient was calculated by summing resource use items 248 
multiplied by unit costs across the in-patient stay and the 12-month postoperative follow-up 249 
period (Appendix B. Table B7). Health state utilities from the EQ-5D-3L and SF-36, based 250 
on UK value sets [15, 23] were used to generate quality-adjusted life years (QALYs) using 251 
the area under the curve method and assigning a value of zero from date of death.  Missing 252 
values were imputed using chained predictive mean matching, stratified by treatment and 253 
conditional on age, sex and baseline EQ-5D-3L. 254 
  255 
Differences in mean costs and QALYs were estimated using seemingly unrelated regression, 256 
controlling for age, sex, valve, baseline EQ-5D-3L and treatment, to accommodate skewness 257 
[24].  Uncertainty in cost-effectiveness was estimated by drawing 1000 bootstrapped samples 258 
and conducting probabilistic sensitivity analysis. Results are presented as incremental net 259 
monetary benefit at various thresholds of willingness to pay per QALY, cost-effectiveness 260 
planes and cost-effectiveness acceptability curves. Deterministic sensitivity analyses explored 261 
effects of using complete cases only, SF6D-based QALY estimates, the procedure inpatient 262 
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admission only, excluding patients who died and excluding additional equipment costs 263 
(Appendix B. Table B11).  264 
 265 
Results 266 
Overall 1024 patients were screened between 28 January 2010 and 13 April 2015, of whom 267 
222 were recruited and randomised to MS (118) or FS (104).  One-year follow-up was 268 
completed on 23 May 2016.  269 
Study groups were similar at baseline except for a non-significant sex imbalance (Table 1). In 270 
this trial, MS was not completed in 14 (12%) of 118 patients randomised to MS. Of these 271 
patients, 6 (5%) had conversion from MS to FS due to reasons listed in Figure 1. The 272 
remaining 8 patients underwent FS after randomisation to MS but without initial MS incision 273 
as MS was considered unsafe/impractical.  The true rate of intraoperative conversion of MS 274 
to FS was therefore 5%. Four patients (2%, Table 2) were censored before discharge: one 275 
withdrawal before surgery (FS) and three deaths (all randomised to and received MS). A 276 
further thirteen (6%) were censored before fitness for discharge: six discharged to acute 277 
hospital (three MS, three FS), seven to long-term care or rehabilitation (three FS, four MS). 278 
Mean time to hospital discharge was longer for MS than FS (9.5 vs. 8.6 days), as was mean 279 
time to fitness to discharge (8.5 vs. 7.5 days). However, distributions of these endpoints were 280 
similar in both groups (Figure 2, Table 2). The difference was not statistically significant in 281 
either primary analyses using Cox models (Figure 3), log-rank tests (Table 2) or sensitivity 282 
analyses (Appendix A. Table A4). The gamma-distributed frailty term in the Cox models was 283 
estimated to have variance 0.006675 for time to fitness and 0.000100 for time to discharge, 284 
suggesting that surgeon heterogeneity was negligible.  285 
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Time to drain removal (including drains inserted/retained to treat complications) was longer 286 
for MS, but times to extubation and independent mobilisation did not differ significantly 287 
between groups (Table 2, Figure 3), nor did numbers of patients re-intubated (six MS vs. five 288 
FS, OR 1.039, CI 0.306-3.531, p=0.9512). Statistically significant HRs indicated longer 289 
surgery, CPB, cross-clamp and theatre times for MS (Figure 3). No significant differences 290 
were seen in blood loss (Appendix A. Table A3), or in numbers of patients requiring 291 
transfusion of blood (50 MS vs. 51 FS, OR 0.797, CI 0.453-1.402, p=0.4310) or clotting 292 
products (11 MS vs 4 FS, OR 2.616, CI 0.801-8.541, p=0.1112). 293 
Regression models for pain at rest, EQ-5D utilities and SF-36 domain scores (Appendix A. 294 
Tables A6, A7, A8) estimated greater rate of improvement over time in MS patients for three 295 
SF-36 domains (social functioning, vitality and role physical). After multiple imputation, the 296 
difference was only significant for the role physical domain (Appendix A. Table A9). Pain on 297 
deep breath was not analysed as only less than half the data were collected due to poor patient 298 
compliance. 299 
 Nine (4%) patients died within a year of surgery: seven (6%) MS, two (2%) FS.  Five deaths 300 
were possibly related to treatment (four MS, one FS), none were probably or definitely 301 
related (Appendix A. Table A15). Overall, twelve (10%) MS and seven (7%) FS patients died 302 
during follow-up (mean follow-up 760 days: 745 MS, 777 FS).  Time to all-cause death, 303 
adjusted for age, showed a moderately large but statistically non-significant HR (MS/FS) of 304 
1.871 (CI 0.723-4.844, p=0.1966). 305 
Safety analyses excluded one patient who was withdrawn before surgery.  There were 306 
significantly more SAEs in MS recipients (rate ratio 1.615, CI 1.070-2.437, p=0.0225) 307 
(Appendix A. Table A11).  The numbers of patients experiencing SAEs were not 308 
significantly different (OR 1.559, CI 0.895-2.715, p=0.1161). Incidence of para-prosthetic 309 
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regurgitation did not differ significantly between groups (Appendix A. Table A13). Seven 310 
patients developed pericardial collection (three MS vs four FS, OR 0.680, CI 0.146-3.178, 311 
p=0.6229).  Wound infections (including superficial and deep infections) were more common 312 
in FS recipients (thirteen FS vs four MS, OR 0.312, CI 0.097-1.005, p=0.0511). Deep sternal 313 
wound infection developed in one MS and one FS recipient, neither of whom required plastic 314 
surgical repair.     315 
Economic analyses are summarised in Table 4. There was additional cost for MS relative to 316 
FS (£1,714 per patient, p=0.0765) in the first year following surgery. MS patients had (non-317 
significant) better EQ-5D-based QALYs (0.03 per patient, p=0.1509). The incremental cost 318 
per QALY gained was £61,379, but after adjusting for baseline characteristics, MS had 319 
higher costs and lower QALYs (i.e. was dominated).  In deterministic and probabilistic 320 
sensitivity analyses, MS was either dominated or had a very large cost per QALY, except for 321 
the complete case analysis (Appendix B. Tables B11, B12).  322 
Discussion 323 
The UK NHS is a free for patient at point-of-delivery healthcare system. Apart from good 324 
recovery, hospital discharge of a significant proportion of elderly patients depends on the 325 
timely availability of social care services in the community.  The Mini-Stern trial is the first 326 
RCT comparing FS and MS for isolated AVR when performed for UK NHS patients.   327 
 328 
In this prospective, pragmatic, open-label RCT, MS did not reduce the total duration of 329 
hospital stay after AVR.  As hospital discharge is sometimes delayed due to social factors, we 330 
included time until fit for discharge as a second primary endpoint.  This was also not reduced 331 
by MS. These endpoints were recorded by physiotherapists based on a common discharge 332 
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protocol with specific clinical milestones to achieve, thereby excluding  physician-induced 333 
bias.  334 
 335 
In this study operation, total theatre, aortic cross-clamp and CPB times were significantly 336 
prolonged with MS. This was expected as in general, minimal access valve operations take 337 
longer [5, 9].  This is justifiable if MS resulted in either faster recovery, shorter postoperative 338 
stay, reduced cost of treatment or more importantly a significant reduction in adverse events 339 
and therefore superior patient safety.  In this RCT, MS did not achieve these benefits and 340 
hence we feel that the prolonged operation time, total theatre, cross-clamp and CPB times are 341 
not justifiable for performing AVR through MS.      342 
 343 
Previously, two meta-analyses [11, 12] concluded that mAVR approaches are superior in 344 
certain aspects of postoperative recovery. However, both included studies on mini-345 
thoracotomy approach for AVR, and therefore inferences drawn cannot be extrapolated to 346 
MS. A retrospective propensity-matched analysis of data from a UK national database 347 
concluded that MS  is safe and comparable to conventional AVR [14]. The authors found 348 
thatMS resulted in a shorter postoperative hospital stay, which disagrees with our findings.  349 
However, a propensity-matched study can suffer from selection bias if its matching algorithm 350 
produces treatment groups that are unbalanced in some unobserved characteristics.  Recently, 351 
a retrospective study demonstrated safety of right thoracotomy minimally invasive isolated 352 
and concomitant AVR in patients of all age groups [25].  As randomisation balances study 353 
groups in known and unknown characteristics, results of the Mini-Stern trial should be more 354 
reliable than non-randomised studies.   355 
 356 
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Previous studies investigating cost-effectiveness provided unclear answers.  A report 357 
analysing registry data from patients who underwent isolated primary AVR [26] reported 358 
lower hospital cost when AVR was performed through right anterior thoracotomy compared 359 
to sternotomy-based approaches with no significant differences in outcome. The main reasons 360 
attributed to lower costs were earlier hospital discharge and reduced use of blood products. 361 
Ghanta et al [27] noted that exclusion of rehabilitation costs could alter this finding. A review 362 
by Glauber et al [13], based on uncontrolled studies, noted that higher cost of instruments and 363 
devices in mAVR could be offset by economic advantage gained by  shorter hospital stay and 364 
lower complication rates.  The Mini-Stern trial assessed cost-effectiveness using a range of 365 
sensitivity analyses, but only the complete case analysis showed MS to be cost-effective, 366 
suggesting lower costs but slightly worse outcomes with  MS.  However, this analysis used a 367 
potentially unrepresentative sample of just 90 patients.   Our analysis was restricted to the 368 
first year following operation without long-term analysis beyond 1 year. 369 
 370 
This RCT is robust with many merits including on-table randomisation, comprehensive and 371 
independent outcome assessment without physician-bias, longer-term clinical assessment, 372 
HRQoL analysis and economic analysis.  However there were some limitations. Although we 373 
report on secondary endpoints, this trial was powered only to address the primary endpoint.  374 
A total of 14 patients (12%) allocated to MS received FS, which could be another limitation.  375 
However, only 6 patients (5%) had true conversion after an attempted MS, while 8 patients 376 
(6.7%) went on to FS for safety reasons.  Although this RCT took place in only two centres, 377 
thereby limiting generalisability, recruitment by eight surgeons improves generalisability.  A 378 
total of 1024 patients were screened to recruit 222 (21.7%) patients.  Although this 379 
potentially suggests selection bias, only 125 eligible patients (12.2%) failed recruitment while 380 
the remaining 667 patients (65.1%) did not meet inclusion criteria.  Blinding was not 381 
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practical as sternotomy dressings were usually changed 48 hours after surgery and patients 382 
became aware of the approach.  This could have caused bias in self-reported outcomes. 383 
Missing ‘pain at rest’ data were unlikely to be missing at random, and therefore imputation 384 
might not have addressed all potential biases. Despite having two primary outcomes, we did 385 
not adjust for multiple testing.  However, as neither showed a significant difference between 386 
groups, this would not have affected our conclusions.   387 
 388 
In conclusion, MS for AVR did not result in quicker recovery or earlier hospital discharge.  389 
MS resulted in longer operations, increased costs, and resulted in more SAEs than FS. 390 
Overall, this pragmatic RCT did not provide evidence that MS results in better clinical or 391 
quality of life outcomes, or that MS is cost-effective compared to FS in the first year after 392 
AVR.  393 
 394 
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Legends 407 
Central Picture Legend:  Duration of hospital stay after AVR: FS versus MS. 408 
Video Legend: MS approach for AVR. 409 
Figure 1. Trial flow diagram.  410 
Figure 2. Kaplan-Meier curves for primary endpoints. Points indicate censoring and dashed 411 
lines represent 95% confidence intervals.  412 
Figure 3. Forest plot of HRs and 95% confidence intervals from Cox models.  413 
 Figure 4. Cost-effectiveness planes. Proportion of points below each threshold gives the 414 
probability that MS is more cost-effective than FS. This probability is 3.7% for willingness to 415 
pay £20,000/QALY and 5.1% for willingness to pay £30,000/QALY. 416 
 417 
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Table 1.   Baseline characteristics 418 
 MS (n = 118) FS (n = 104) 
Age (years) - Mean (SD) 71.3 (12.3) 72.1 (10.9) 
BMI (kg/m2) – Mean (SD) 26.6 (3.2) 27.7 (3.7) 
Sex - frequency (%)   
Female 53 (45%) 57 (55%) 
Male 65 (55%) 47 (45%) 
Valve type - frequency (%)   
Mechanical 15 (13%) 14 (13%) 
Tissue 103 (87%) 90 (87%) 
EuroSCORE (%) - Mean (SD) 5.9 (2.1) * 6.1 (2.1) 
* EuroSCORE was missing for one MS patient. 419 
 420 
 421 
 422 
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Table 2. Kaplan-Meier medians (quartiles) for time-to-event endpoints 423 
 MS (n = 118) FS (n = 104) p-value* 
Time to discharge (days) 7 (6, 10) 7 (6, 10)  0.6924 
Censored 3 1  
Time until fit for discharge (days) 6 (5, 10) 6 (5, 9) 0.5597 
Censored 10 7  
Time to independent mobilisation (days) 4 (3, 7) 4 (3, 6)  0.5819 
Censored 8 7  
Time to mediastinal drain removal (hours) 26.1 (20.6, 53.3) 22.5 (19.4, 37.8)  0.0157 
Censored 2 2  
Time to extubation (hours) 9.2 (7.8, 12.1) 8.3 (6.8, 11.7)  0.5488 
Censored 1 1  
Theatre time (minutes) 191 (172, 225) 176 (152, 203) < 0.0001 
Censored 0 0  
CPB time (minutes) 80 (70, 95) 66 (52, 85)  < 0.0001 
Censored 0 0  
Cross-clamp time (minutes) 65 (53, 76) 49 (39, 64)  < 0.0001 
Censored 0 0  
Surgery duration (minutes) 163 (139, 190) 149 (114, 167)  < 0.0001 
Censored 3 4  
*Log-rank test. Seven surgery durations were not recorded and censored at 1 minute.  424 
  425 
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Table 3. Costs, QALYs and Cost-effectiveness 426 
 Cost and QALYs  
(with imputation)  
 
FS (n = 118) MS (n = 104) 
Mean Cost 
per patient 
SD Mean Cost 
per patient 
SD 
Primary Admission 
Costs 
Theatre use £3,824 £1,243 £4,422 £2,053 
Additional surgical items £16.52 £0.0 £52.0 £0.0 
Critical care (ITU) £1,834 £3,023 £2,934 £5,030 
Cardiac ward £2,744 £1,664 £2,676 £1,500 
Physio- and Occupational Therapy £77 £55 £78 £68 
Rehabilitation £384 £1,878 £263 £1,621 
Acute hospital £347 £1,919 £298 £1,971 
Sub-total cost £9,226 £6,511 £10,724 £8,850 
Post primary 
admission costs to 
12 months 
Hospital Re-admission £418 £1,475 £575 £1,863 
Follow up tests £224 £258 £282 £279 
Follow up healthcare visits £373 £359 £311 £263 
           Sub-total cost £1,015 £1,778 £1,168 £2,079 
 
Drugs 
 
£379 
 
£548 
 
£441 
 
£977 
Total cost over 12 months £10,620 £7,624 £12,333 £9,864 
Incremental cost- 
effectiveness*  
(probabilistic 
analysis with 
baseline 
Incremental cost at 12 months (MS-FS) £2,154.0 (SE £36) 
Incremental EQ-5D-3L QALYs (MS-FS) -0.0122 (SE 0.0008) 
ICER MS dominated by FS 
NMB (at WTP £20,000/QALY) -£2,397 
NMB (at WTP £30,000/QALY) -£2,519 
 24 
 
adjustment) 
SD: standard deviation, SE: standard error, WTP: willingness to pay, NMB: net monetary benefit, ICER: incremental 
cost-effectiveness ratio.  * Incremental costs and effects estimated using SUR, adjusting for baseline differences. 
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